An effect comparison of teriparatide and bisphosphonate on posterior lumbar interbody fusion in patients with osteoporosis: a prospective cohort study and preliminary data

Pyung Goo Cho, Gyu Yeul Ji, DongAh Shin, Yoon Ha, Do Heum Yoon, Keung Nyun Kim

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Purpose: Our purpose was to evaluate the efficacy of teriparatide for posterior lumbar interbody fusion (PLIF) in osteoporotic women. Methods: Forty-seven osteoporotic patients underwent PLIF with pedicle screw fixation for degenerative lumbar stenosis and instability. Patients were divided into two groups. The teriparatide group (n = 23) was injected subcutaneously with teriparatide (20 μg daily) for 3-month cycles alternating with 3-month periods of oral sodium alendronate for 12 months. The bisphosphonate group (n = 24) was administered oral sodium alendronate (91.37 mg/week) for ≥1 year. Serial plain radiography, computed tomography, and bone mineral densitometry (BMD) evaluations were performed. Fusion rate, bony fusion duration, and T score changes were evaluated. Clinical data [pain scores, Prolo’s functional scale, and Oswestry disability index (ODI)] were also serially evaluated. Results: The teriparatide group showed earlier fusion than the bisphosphonate group. The average period of bone fusion was 6.0 ± 4.8 months in the teriparatide group but 10.4 ± 7.2 months in the bisphosphonate group. The bone fusion rate in the teriparatide group was higher than that in the bisphosphonate group at 6 months; however, there was no difference 12 and 24 months after surgery. Pain scores and ODI were not significantly different between groups. BMD scores in the teriparatide group were significantly improved compared with the bisphosphonate group 2 years after surgery. Conclusions: There was no significant improvement in overall fusion rate and clinical outcome in our patients after injection of teriparatide, but the teriparatide group showed faster bony union and highly improved BMD scores.

Original languageEnglish
Pages (from-to)691-697
Number of pages7
JournalEuropean Spine Journal
Volume26
Issue number3
DOIs
Publication statusPublished - 2017 Mar 1

Fingerprint

Teriparatide
Diphosphonates
Osteoporosis
Cohort Studies
Prospective Studies
Densitometry
Bone and Bones
Minerals
Alendronate
Pain
Radiography
Pathologic Constriction
Tomography

All Science Journal Classification (ASJC) codes

  • Surgery
  • Orthopedics and Sports Medicine

Cite this

@article{d6c2225a26bd4efbaa347050d6c1f53d,
title = "An effect comparison of teriparatide and bisphosphonate on posterior lumbar interbody fusion in patients with osteoporosis: a prospective cohort study and preliminary data",
abstract = "Purpose: Our purpose was to evaluate the efficacy of teriparatide for posterior lumbar interbody fusion (PLIF) in osteoporotic women. Methods: Forty-seven osteoporotic patients underwent PLIF with pedicle screw fixation for degenerative lumbar stenosis and instability. Patients were divided into two groups. The teriparatide group (n = 23) was injected subcutaneously with teriparatide (20 μg daily) for 3-month cycles alternating with 3-month periods of oral sodium alendronate for 12 months. The bisphosphonate group (n = 24) was administered oral sodium alendronate (91.37 mg/week) for ≥1 year. Serial plain radiography, computed tomography, and bone mineral densitometry (BMD) evaluations were performed. Fusion rate, bony fusion duration, and T score changes were evaluated. Clinical data [pain scores, Prolo’s functional scale, and Oswestry disability index (ODI)] were also serially evaluated. Results: The teriparatide group showed earlier fusion than the bisphosphonate group. The average period of bone fusion was 6.0 ± 4.8 months in the teriparatide group but 10.4 ± 7.2 months in the bisphosphonate group. The bone fusion rate in the teriparatide group was higher than that in the bisphosphonate group at 6 months; however, there was no difference 12 and 24 months after surgery. Pain scores and ODI were not significantly different between groups. BMD scores in the teriparatide group were significantly improved compared with the bisphosphonate group 2 years after surgery. Conclusions: There was no significant improvement in overall fusion rate and clinical outcome in our patients after injection of teriparatide, but the teriparatide group showed faster bony union and highly improved BMD scores.",
author = "Cho, {Pyung Goo} and Ji, {Gyu Yeul} and DongAh Shin and Yoon Ha and Yoon, {Do Heum} and Kim, {Keung Nyun}",
year = "2017",
month = "3",
day = "1",
doi = "10.1007/s00586-015-4342-y",
language = "English",
volume = "26",
pages = "691--697",
journal = "European Spine Journal",
issn = "0940-6719",
publisher = "Springer Verlag",
number = "3",

}

An effect comparison of teriparatide and bisphosphonate on posterior lumbar interbody fusion in patients with osteoporosis : a prospective cohort study and preliminary data. / Cho, Pyung Goo; Ji, Gyu Yeul; Shin, DongAh; Ha, Yoon; Yoon, Do Heum; Kim, Keung Nyun.

In: European Spine Journal, Vol. 26, No. 3, 01.03.2017, p. 691-697.

Research output: Contribution to journalArticle

TY - JOUR

T1 - An effect comparison of teriparatide and bisphosphonate on posterior lumbar interbody fusion in patients with osteoporosis

T2 - a prospective cohort study and preliminary data

AU - Cho, Pyung Goo

AU - Ji, Gyu Yeul

AU - Shin, DongAh

AU - Ha, Yoon

AU - Yoon, Do Heum

AU - Kim, Keung Nyun

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Purpose: Our purpose was to evaluate the efficacy of teriparatide for posterior lumbar interbody fusion (PLIF) in osteoporotic women. Methods: Forty-seven osteoporotic patients underwent PLIF with pedicle screw fixation for degenerative lumbar stenosis and instability. Patients were divided into two groups. The teriparatide group (n = 23) was injected subcutaneously with teriparatide (20 μg daily) for 3-month cycles alternating with 3-month periods of oral sodium alendronate for 12 months. The bisphosphonate group (n = 24) was administered oral sodium alendronate (91.37 mg/week) for ≥1 year. Serial plain radiography, computed tomography, and bone mineral densitometry (BMD) evaluations were performed. Fusion rate, bony fusion duration, and T score changes were evaluated. Clinical data [pain scores, Prolo’s functional scale, and Oswestry disability index (ODI)] were also serially evaluated. Results: The teriparatide group showed earlier fusion than the bisphosphonate group. The average period of bone fusion was 6.0 ± 4.8 months in the teriparatide group but 10.4 ± 7.2 months in the bisphosphonate group. The bone fusion rate in the teriparatide group was higher than that in the bisphosphonate group at 6 months; however, there was no difference 12 and 24 months after surgery. Pain scores and ODI were not significantly different between groups. BMD scores in the teriparatide group were significantly improved compared with the bisphosphonate group 2 years after surgery. Conclusions: There was no significant improvement in overall fusion rate and clinical outcome in our patients after injection of teriparatide, but the teriparatide group showed faster bony union and highly improved BMD scores.

AB - Purpose: Our purpose was to evaluate the efficacy of teriparatide for posterior lumbar interbody fusion (PLIF) in osteoporotic women. Methods: Forty-seven osteoporotic patients underwent PLIF with pedicle screw fixation for degenerative lumbar stenosis and instability. Patients were divided into two groups. The teriparatide group (n = 23) was injected subcutaneously with teriparatide (20 μg daily) for 3-month cycles alternating with 3-month periods of oral sodium alendronate for 12 months. The bisphosphonate group (n = 24) was administered oral sodium alendronate (91.37 mg/week) for ≥1 year. Serial plain radiography, computed tomography, and bone mineral densitometry (BMD) evaluations were performed. Fusion rate, bony fusion duration, and T score changes were evaluated. Clinical data [pain scores, Prolo’s functional scale, and Oswestry disability index (ODI)] were also serially evaluated. Results: The teriparatide group showed earlier fusion than the bisphosphonate group. The average period of bone fusion was 6.0 ± 4.8 months in the teriparatide group but 10.4 ± 7.2 months in the bisphosphonate group. The bone fusion rate in the teriparatide group was higher than that in the bisphosphonate group at 6 months; however, there was no difference 12 and 24 months after surgery. Pain scores and ODI were not significantly different between groups. BMD scores in the teriparatide group were significantly improved compared with the bisphosphonate group 2 years after surgery. Conclusions: There was no significant improvement in overall fusion rate and clinical outcome in our patients after injection of teriparatide, but the teriparatide group showed faster bony union and highly improved BMD scores.

UR - http://www.scopus.com/inward/record.url?scp=84949567775&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949567775&partnerID=8YFLogxK

U2 - 10.1007/s00586-015-4342-y

DO - 10.1007/s00586-015-4342-y

M3 - Article

C2 - 26661639

AN - SCOPUS:84949567775

VL - 26

SP - 691

EP - 697

JO - European Spine Journal

JF - European Spine Journal

SN - 0940-6719

IS - 3

ER -